| 517.26 3.67 (0.71%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 622.18 | 1-year : | 652.91 |
| Resists | First : | 532.69 | Second : | 559 |
| Pivot price | 518.25  |
|||
| Supports | First : | 490.13 | Second : | 407.78 |
| MAs | MA(5) : | 515.67 |
MA(20) : | 518.01 |
| MA(100) : | 495.96 |
MA(250) : | 447.21 |
|
| MACD | MACD : | 1.6 |
Signal : | 3.2 |
| %K %D | K(14,3) : | 35.7 |
D(3) : | 35.4 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 615 | Low : | 265 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MDGL ] has closed above bottom band by 47.9%. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 521.67 - 523.77 | 523.77 - 525.94 |
| Low: | 501.93 - 504.1 | 504.1 - 506.33 |
| Close: | 513.68 - 517.47 | 517.47 - 521.38 |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Mon, 25 May 2026
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 30% Upside Beckons in the Biotech Sector - DirectorsTalk Interviews
Fri, 22 May 2026
Insider Sell: Richard Levy Sells Shares of Madrigal Pharmaceuticals Inc (MDGL) - GuruFocus
Fri, 22 May 2026
Director Richard Levy of Madrigal (MDGL) sells 5,682 shares under plan - Stock Titan
Fri, 22 May 2026
[144] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Thu, 21 May 2026
Madrigal hires 15 staff, grants 5,308 stock units vesting over 4 years - Stock Titan
Thu, 21 May 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 106.7 (%) |
| Shares Short | 3,850 (K) |
| Shares Short P.Month | 3,910 (K) |
| EPS | -13.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 23.57 |
| Profit Margin | -27.4 % |
| Operating Margin | -29.8 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -49.4 % |
| Qtrly Rev. Growth | 126.8 % |
| Gross Profit (p.s.) | 45.53 |
| Sales Per Share | 49 |
| EBITDA (p.s.) | -13.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -268 (M) |
| Levered Free Cash Flow | -156 (M) |
| PE Ratio | -38.29 |
| PEG Ratio | 0 |
| Price to Book value | 21.93 |
| Price to Sales | 10.55 |
| Price to Cash Flow | -44.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|